查詢結果分析
來源資料
相關文獻
- Transcatheter Arterial Immunochemo-embolization for the Treatment of Unresectable Alpha-fetoprotein-positive Hepatocellular Carcinoma
- Treatment of Hepatocellular Carcinoma Smaller Than 5 CM by Transcatheter Arterial Chemoembolization
- Pulmonary Embolism after Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: Report of a Case
- Long-Term Survival of Taiwanese Patients with Hepatocellular Carcinoma after Combination Therapy with Transcatheter Arterial Chemoembolization and Percutaneous Ethanol Injection
- 一位行經導管動脈栓塞術肝癌患者之護理經驗
- Fatal Liver Abscess and Tumor Rupture after Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma
- 肝癌經導管動脈化學栓塞術之護理
- 肝細胞癌經皮射頻高溫燒灼術前後之磁振造影變化
- The Outcome of Hepatocellular Carcinoma Treated with Transcatheter Arterial Chemoembolization
- 臨床肝細胞癌經動脈導管栓塞術
頁籤選單縮合
題 名 | Transcatheter Arterial Immunochemo-embolization for the Treatment of Unresectable Alpha-fetoprotein-positive Hepatocellular Carcinoma=肝動脈免疫化學栓塞術治療胎兒蛋白升高性無法切除之原發性肝細胞癌 |
---|---|
作 者 | 姜仁惠; 黃振義; 李潤川; 曾修山; 邱怡友; 周宜宏; 王家槐; 鄭慧正; 鄧木火; 淩憬峰; 陳行素; 雷永耀; 李壽東; 張政彥; | 書刊名 | 中華放射線醫學雜誌 |
卷 期 | 25:3 2000.06[民89.06] |
頁 次 | 頁113-117 |
分類號 | 415.5362 |
關鍵詞 | 動脈; 栓塞術; 肝細胞癌; 化學栓塞術; Arteries; Embolization; Hepatocellular carcinoma; Chemoembolization; Interferon; OK-432; |
語 文 | 英文(English) |
中文摘要 | 20 位病人因患有胎兒蛋白升高性已無法切除之肝細胞癌,因其肝功能尚佳而安排肝動脈免疫化學栓塞治療 (TIE),以評估其療效和安全性。接受 TIE 治療之病人先由肝動脈注射 dexorubicin,mitomycin C 和 lipiodol 之混合懸浮液,然後注射 interferon-gamma 和 OK- 432 溶液,溶液中混有少量 gelfoam 小碎片。最後注射含有 gelfoam 小碎片之 actinomycin D 溶液,直到腫瘤血管被塞住為止。為了客觀了解 TIE 療效,我們把同時期傳統 TAE 治療之 79 位同質性病人篩選出來比較。TAE 治療群之 1、2、3 年存活率為 55.6%、50.0%、18.8%;TIE 治療群為 66.7%、40.0%、21.4%。TIE 治療群病人於治療後多數發生體溫上升、上腹疼痛、噁心嘔吐現象。有一位病人高燒 40°C,血壓嚴重上升。病人用藥物治療後症狀消失。我們之臨床試驗顯示:對於胎兒蛋白上升無法手術切除之肝癌病人,TIE 治療還算安全,但並不比傳統 TAE 有效。 |
英文摘要 | Transcatheter arterial immunochemo-embolization(TIE) was used to treat 20 patients with unresectable alpha-fetoprotein-positive hepatocellular carcinoma (HCC) without severe liver dysfunction. The purpose of this study was to evaluate the therapeutic potential and tolerability of TIE. Transcatheter arterial immunochemo-embolization was carried out through hepatic arterial catheterization and injection of a mixture of doxorubicin, mitomycin C and iodized oil into the feeding arteries of tumors followed by injections of gelatin sponge particles in OK-432 and interferon-gamma solution. Finally, the tumor vessels were occluded using gelatin sponge particles in actinomycin D solution. The results of the 20 patients were compared with 79 patients who underwent conventional transcatheter arterial chemoembolization (TAE) during the same period. The cumulative survival rates of the patients treated using TIE at 1-, 2- and 3-year were 66.7%, 40.0% and 21.4%, respectively. The corresponding rates for patients treated using TAE were 55.6%, 50.0% and 18.8%, respectively. No serious complications were found in patient treated using TIE except that high fever and elevation of blood pressure occurred in one patient. In conclusion, transcatheter arterial immunochemo-embolization was safe but did not offer a better therapeutic efficacy for unresectable AFP-positive primary HCC than conventional TAE. |
本系統中英文摘要資訊取自各篇刊載內容。